General discussion, page-17568

I'm sure there are. Have at it.
If you find that at one point, they hoped to put IHL-216a through Phase 1 in the next 2 years, congratulations: welcome to biotech startup land. Timelines slip - it is to be expected. Furthermore, they probably STILL hope to initiate a Phase 1 trial for that asset in the next 2 years. They simply can't do it right this minute.

I'm not sure you should be investing in biotech startups if any of this is surprising to you.